Peles Therapeutics
Monoclonal Antibody Treatment for Peripheral Artery Disease
Health Tech & Life Sciences
Non Active, Aug 2022 ceased to operate
Company Overview
Snapshot
Founded in May 2021, Peles Therapeutics operates with 1–10 employees. The company secured its seed funding in July 2021 from Israel Biotech Fund, marking a key early milestone in its development.
Business overview
Peles Therapeutics is a Health Tech & Life Sciences company focused on developing a humanized monoclonal antibody treatment. The company's core technology targets the receptor for advanced glycation end products, aiming to address the unmet medical needs of diabetic patients suffering from peripheral artery disease. Operating within the Pharmaceuticals sector, Peles Therapeutics is engaged in drug discovery and development, utilizing biological molecules to create novel therapeutics.
Log in to access full profile ›Company Intelligence Q&A
- What is Peles Therapeutics' primary focus?
- Peles Therapeutics is developing a humanized monoclonal antibody treatment specifically targeting the receptor for advanced glycation end products, with an initial focus on peripheral artery disease in diabetic patients.
- When was Peles Therapeutics founded?
- Peles Therapeutics was founded in May 2021.
- What is the status of Peles Therapeutics?
- Peles Therapeutics is non-active, having ceased operations in August 2022.
- What technology does Peles Therapeutics utilize?
- Peles Therapeutics utilizes technology in-licensed from Columbia University for its monoclonal antibody development.